Coya Therapeutics (COYA) vs Tonix Pharmaceuticals (TNXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Coya Therapeutics (COYA) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, losing 33.2% versus a loss of 67.6%. Tonix Pharmaceuticals is the larger company by market cap ($103.6 million vs $99.7 million), about 1.0 times the size, while Coya Therapeutics is growing revenue faster (+123.6% vs +29.8%). Coya Therapeutics converts more of its revenue into profit, with a net margin of -267.1% versus -946.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COYA | TNXP |
|---|---|---|
| Share price | $4.25 | $6.04 |
| Market cap | $99.70M | $103.59M |
| 1-day change | -2.07% | -5.92% |
| YTD return | -26.72% | -61.33% |
| 1-year return | -33.18% | -67.56% |
| 5-year return | — | -100.00% |
| EPS (TTM) | $-1.07 | $-13.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.95M | $13.11M |
| Revenue growth (YoY) | +123.57% | +29.85% |
| Net income (latest FY) | $-21.23M | $-124.02M |
| Gross margin | — | 49.34% |
| Operating margin | -283.87% | -959.05% |
| Net margin | -267.14% | -946.22% |
| 52-week high | $7.55 | $20.58 |
| 52-week low | $3.71 | $6.01 |
| Distance from 52-week high | -43.71% | -70.65% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +257.88% | +636.75% |
| Average volume | 140.71K | 607.68K |
| Shares outstanding | 23.46M | 17.15M |
| Employees | 8 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COYA has outperformed TNXP by 34.4 percentage points over the past year.
- Coya Therapeutics is more profitable, keeping -267.1 cents of every revenue dollar as net income versus -946.2 cents for Tonix Pharmaceuticals.
- Coya Therapeutics grew revenue faster in its latest fiscal year (+123.57% vs +29.85%).
About Coya Therapeutics
COYA stock →Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Tonix Pharmaceuticals
TNXP stock →Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees
COYA vs TNXP FAQ
Which is bigger, Coya Therapeutics or Tonix Pharmaceuticals?
Tonix Pharmaceuticals (TNXP) is larger, with a market capitalization of $103.59M compared with $99.70M for Coya Therapeutics (COYA).
Which stock has performed better over the past year, COYA or TNXP?
COYA returned -33.18% over the past 12 months, compared with -67.56% for TNXP (price return, excluding dividends). Past performance does not predict future results.
Are Coya Therapeutics and Tonix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.